Myeloid Mutations Register in R/R CML

ABL Mutation Register in Patients With ITK Relapsed or Refractory Chronic Myeloid Leukemia

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05080829

Enrollment

Registered

2021-10-18

Start date

2021-03-01

Completion date

2022-03-30

Last updated

2021-10-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Myeloid Leukaemia Recurrent, Chronic Myeloid Leukemia, in Relapse

Keywords

chronic myeloid leukemia

Brief summary

The aim of the study is to know the percentage of ABL mutations in patients with chronic myeloid leukemia that relapsed or are refractory to tyrosine-kinase inhibitors measured with a myeloid mutations panel by NGS.

Interventions

DIAGNOSTIC_TESTMyeloid mutations measurement

Measure of myeloid mutations by NGS when detection of refractory or relapsed CML is done

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* CML diagnosis by the WHO 2016 criteria * Failure to reach cytogenetic response of Ph chromosome of 36 to 95% at 3 months or BCR/ABL \<10% at 6 months of treatment with TKI * Progression or relapse of the disease after previous response to treatment with TKI * Validation of adherence to treatment * Inform consent

Exclusion criteria

* Lack of information to complete the register * Failure to response achievement due lack of adherence to treatment

Design outcomes

Primary

Measure	Time frame	Description
Presence of myeloid mutations by Next Generation Sequence	1 year	Detection of positive myeloid mutations at detection of relapse or refractoriness to ITK treatment

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026